About US
Contact us
-
Pfizer still unable to get on top of problems at Hospira injectables plantSince Pfizer’s Kansas plant received an FDA warning letter last year, the company has insisted it is making good progress on turning things around at the essential but troubled injectables facility. B2018/12/13
-
As competition heats up, U.S. prices for Remicade and biosims slip: analystAs Johnson & Johnson vies with biosimilars to its big-selling Remicade, prices across the category are gradually falling, an analyst says—and Pfizer's Inflectra has taken the biggest tumble. Th2018/12/13
-
Merck promotes oncology, vaccine executives to replace Adam Schechter in commercial rejigMerck & Co. boasted some major success in the sales department this year, but the company’s commercial organization will still get a makeover for 2019. On Monday, the New Jersey company said Adam2018/12/12
-
China's Zhejiang Huahai lambasted in FDA warning letter for putting profits ahead of safetyThe Chinese API maker at the heart of a global scare and recall of blood pressure medicines has been savaged in an FDA warning letter for failing to uncover a suspected carcinogen in its APIs when a c2018/12/12
-
Acadia debuts first Nuplazid branded ads, aiming to spark talk of Parkinson's psychosisWith an FDA safety review in the rearview mirror, Acadia is back to business on Parkinson's psychosis therapyNuplazid—and launching its first branded ad campaign to boot. The Nuplazid TV ads made the2018/12/11
-
AstraZeneca kicks off second blood cancer launch, this time for orphan drug LumoxitiFor the second straight year, AstraZeneca is spending the fall launching a hemo-oncology drug. The company is in the process of rolling out Lumoxiti, a treatment for patients with the rare disease ha2018/12/11
-
Bausch Health inks $200M ‘stalking horse’ deal for bankrupt Trulance maker SynergyCould a still-recovering company buying a distressed one create a better business? Bausch Health apparently thinks so when it comes to Synergy Pharma, as it's agreed to pay $200 million for the now-ba2018/12/10
-
Boehringer Ingelheim chops 295 jobs in France but vows $380M in animal health investmentsWhen German pharma Boehringer Ingelheim completed a $12.5 billion asset swap with France’s Sanofi in 2016, BI traded its consumer health business for Sanofi’s veterinary unit andagreedto make the Fren2018/12/10
-
Roche’s Tecentriq gets FDA priority review to treat small cell lung cancerThe US Food and Drug Administration (FDA) has granted priority review for Roche’s Tecentriq (atezolizumab) in combination with chemotherapy for treating extensive-stage small cell lung cancer (ES – SC2018/12/7
-
Novartis, aiming to protect blockbuster sales, advances Xolair follow-up to phase 3With blockbuster Xolair aging, Novartis is looking to usher in a successor to protect its sales. And it got one step closer this week. The Swiss drugmaker willadvancecandidate ligelizumab—a treatment2018/12/7